GCG and metabolic dysfunction-associated steatotic liver disease: Nowadays, Tirzepatide, a molecule with combined agonist action on GLP1 and glucose-dependent insulinotropic peptide, has demonstrated effectiveness in weight loss and improvement in metabolic parameters (especially glucose control), as well as in NAFLD markers.